A fruitful learning did DC showcase Despite the jet lag, the snow and the haze FOURIER and SPIRE tried PCSK9 Evolocumab and Bococizumab Stats looked fine EBBINGHAUS confirmed, Cognition doesn't fail Lowering lipids, a whole new trail. TAVR beat the scalpel in intermediate risk DEFINE FLAIR say bye to FFR; IFR makes procedure brisk DECISION CTO proved that OMT is strong PCI only if symptoms go wrong FFR guided multi-vessel PCI is clean COMPARE ACUTE has clearly signaled it green Post surgical, when LV become bad LEVO CTS says Levosimendan add Treatment of VTE is not an easy guess 'Rivoroxaban' says EINSTEIN CHOICE HDL mimetics and 'Inclisiran' Showed promise in Atherosclerosis in CARAT and ORION A fruitful learning did DC showcase Despite the jet lag, the snow and the haze I learnt End-points, p value and all the MACE Didn't miss the cherry blossom, the Smithsonian aerospace.
(DC -Washington DC; FOURIER -Further cardiovascular outcome research with PCSK9 in subjects with elevated risk; SPIRE -Studies of PCSK9 inhibition and reduction of vascular events; PCSK9 -Proprotein convertase subtilisin/kexin type 9; EBBINGHAUS -Evaluating PCSK9 binding antibody influence on cognitive health in high cardiovascular risk subjects; DECISION CTO -Drug eluting stent implantation versus optimal medical treatment in patients with chronic total occlusion; OMTOptimal medical treatment; PCI -Percutaneous coronary intervention; FFR -Fractional flow reserve; IFR -Instantaneous wave free ratio; COMPARE ACUTE -Comparison between FFR guided revascularization versus conventional strategy in acute MI patients with multivessel disease; LEVO CTS -Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery requiring cardiopulmonary bypass; EINSTEIN CHOICE -Reduced dose rivaroxaban in the long term prevention of recurrent symptomatic venous thromboembolism; CARAT -CER 001 Atherosclerosis regression ACS trial; ORION 1 -Inclisiran, a novel siRNA in LDLC reduction; MACE -Major adverse cardiac events.)
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